Virtual Rounds 2022 Program

Cardiology Track
Heart Failure: The Multiverse of Therapy
Lauren Eyadiel, PA-C

From the 1980s through the early 2000s, there was little medical innovation in the field of heart failure therapies. But in 2014, angiotensin and neprilysin inhibitors were introduced and medical therapy in heart failure has been booming ever since.
Cardiology PA Lauren Eyadiel will present on these new therapies with the objective to:
  1. Define the four pillars of heart failure therapies.
  2. Identify the newer therapies that have been available since 2014.
  3. Present methods for overcoming barriers for prescribing the newer therapies.
Valvular Heart Disease
Lyle W. Larson, PhD, PA-C, DFAAPA

As many as 11.6 million Americans have heart valve disease, and it is not limited to just adults. Congenital heart disease frequently includes valvular defects and affects 40,000 births a year in the U.S. PAs will commonly encounter valvular heart disease in their practices regardless of specialty. It is imperative that they know how to differentiate between benign and potentially lethal outcomes.

Participants in this session will learn:
  1. Evaulation of patients with known or suspected native valvular heart disease
  2. Diagnosis and follow up based upon specific valvular heart disease
  3. Basic principles of medical therapy
  4. Surgical and interventional approaches to treatment
  5. Patient management following valve intervention
  6. Antothrombotic therapies, current and on the horizon
Time is Tissue: Leveraging the Latest ACC/AHA 2021 Chest Pain Guidelines

Cardiovascular disease (CVD) has been and still is the leading cause of adult deaths in the US. In the course of treating acute and chronic CVD, patients often receive multiple new medications and recommendations for post-hospital rehabilitation that is sometimes overwhelming. PAs can facilitate optimal recovery by implementing guideline-directed therapies for both acute and chronic CVD.
Participants of this course will:
  1. Learn common symptom manifestations of acute atherosclerotic disease and the purpose of evaluation via biomarkers, electrocardiography, and stress testing.
  2. Learn acute management of NSTE-ACS and STEMI and the therapies for the reduction of future ASCVD events.
  3. Review available patient-centered modalities to improve shared decision-making.
What You Should Really Know About Peripheral Arterial Disease (PAD)
Robert Ross, PA-C

What has increasingly been recognized is that if an individual has blocked arteries in the legs, they are also very likely to have blocked arteries in the heart and the brain. Peripheral Arterial Disease (PAD) is a very strong independent predictor of having heart attacks and strokes and so it deserves attention for that reason alone. 

Orchestrated efforts among healthcare providers, researches, expert organizations, and healthcare organizations will be needed to increase awareness and understanding of PAD and improve the diagnostic approaches, management, and prognosis of PAD.

In this lecture, cardiology and endocrinology expert Robert Ross, PA-C, will cover the following to help primary care providers develop an excellent cardiovascular prevention program for all their at-risk patients:
  1. Review the risks as defined by the American Heart Association (AHA), American College of Cardiology (ACC) and American Diabetes Assocation (ADA) for patients who have potential PAD
  2. Present a test for PAD that is 95% accurate
  3. Present treatments for patients with PAD